Research · news
FDA advisers back six peptides for pharmacy compounding In a divided two-day meeting, the Pharmacy Compounding Advisory Committee supported BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, while rejecting Emideltide. The votes do not approve the peptides or immediately authorize their use in patient-specific pharmacy compounding.